NCT04304898 An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology
| NCT ID | NCT04304898 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Pulmonary Fibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2020-05-01 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2020-05-01 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The I-FILE study is a prospective multicenter, multinational observational study where the feasibility of a patient-led registry using home monitoring in patients with pulmonary fibrosis will be evaluated. The aim of the study is to gain more insights in disease behavior in patients with pulmonary fibrosis, so in future patients with progressive disease can be better identified.
Eligibility Criteria
Inclusion Criteria: Newly diagnosed patients with F-ILD according to the ATS/ERS criteria by a multidisciplinary ILD team : * MDT diagnosis ≤ 6 months before inclusion * Treatment for F-ILD ≤ than 1 month Exclusion Criteria: * Not able to speak, read or write in the native language of the country where the patient is included * Not able to comply to the study protocol, according to the judgement of the investigator and/or patient * No access to internet
Contact & Investigator
Marlies Wijsenbeek, MD PhD
PRINCIPAL INVESTIGATOR
Erasmus Medical Center
Frequently Asked Questions
Who can join the NCT04304898 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04304898 currently recruiting?
Yes, NCT04304898 is actively recruiting participants. Contact the research team at m.wijsenbeek-lourens@erasmusmc.nl for enrollment information.
Where is the NCT04304898 trial being conducted?
This trial is being conducted at Rotterdam, Netherlands, Rotterdam, Netherlands.
Who is sponsoring the NCT04304898 clinical trial?
NCT04304898 is sponsored by Erasmus Medical Center. The principal investigator is Marlies Wijsenbeek, MD PhD at Erasmus Medical Center. The trial plans to enroll 700 participants.